Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma.
暂无分享,去创建一个
H. Goldschmidt | G. Morgan | P. Sonneveld | W. Gregory | N. Dickens | B. Walker | F. Ross | F. Davies | B. V. Van Ness | B. Durie | J. Child | H. Lokhorst | David C. Johnson | S. Corthals | David C. Johnson | B. Walker
[1] A. Daly,et al. Genome-wide association studies in pharmacogenomics , 2010, Nature Reviews Genetics.
[2] O. Stephens,et al. Genetic polymorphisms of EPHX1, Gsk3β, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma , 2009, Leukemia.
[3] Xiang Chen,et al. Willows: a memory efficient tree and forest construction package , 2009, BMC Bioinformatics.
[4] S. Iida,et al. A pharmacokinetic study evaluating the relationship between treatment efficacy and incidence of adverse events with thalidomide plasma concentrations in patients with refractory multiple myeloma. , 2009, Clinical lymphoma & myeloma.
[5] Faith,et al. Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. , 2008, Blood.
[6] M. Steinbach,et al. Genomic variation in myeloma: design, content, and initial application of the Bank On A Cure SNP Panel to detect associations with progression-free survival , 2008, BMC medicine.
[7] A. Argyriou,et al. A review on oxaliplatin-induced peripheral nerve damage. , 2008, Cancer treatment reviews.
[8] S. Steinberg,et al. ABCB1 genetic variation influences the toxicity and clinical outcome of patients treated with docetaxel , 2008 .
[9] Hua Jiang,et al. Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide-based regimens in multiple myeloma , 2007, Haematologica.
[10] Manuel A. R. Ferreira,et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. , 2007, American journal of human genetics.
[11] Min Goo Lee,et al. MRP2 haplotypes confer differential susceptibility to toxic liver injury , 2007, Pharmacogenetics and genomics.
[12] Lippincott-Schwartz,et al. Supporting Online Material Materials and Methods Som Text Figs. S1 to S8 Table S1 Movies S1 to S3 a " Silent " Polymorphism in the Mdr1 Gene Changes Substrate Specificity Corrected 30 November 2007; See Last Page , 2022 .
[13] H. Kroemer,et al. Influence of polymorphisms of ABCB1 and ABCC2 on mRNA and protein expression in normal and cancerous kidney cortex , 2007, The Pharmacogenomics Journal.
[14] S. Steinberg,et al. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. , 2006, European journal of cancer.
[15] M. Huang,et al. A Mechanistic Study on Reduced Toxicity of Irinotecan by Coadministered Thalidomide, a Tumor Necrosis Factor-α Inhibitor , 2006, Journal of Pharmacology and Experimental Therapeutics.
[16] H. Adelsberger,et al. Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: Final results of a randomised, controlled, multicenter phase II study , 2006, Investigational New Drugs.
[17] Cheng Li,et al. Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma. , 2006, Blood.
[18] L. Mileshkin,et al. The troublesome toxicity of peripheral neuropathy with thalidomide , 2006, Leukemia & lymphoma.
[19] Yi Dai,et al. Induction of plasminogen activator inhibitor-1 and -2 in dorsal root ganglion neurons after peripheral nerve injury , 2005, Neuroscience.
[20] Joshua T. Burdick,et al. Mapping determinants of human gene expression by regional and genome-wide association , 2005, Nature.
[21] B. Palmer,et al. Metabolism of Thalidomide in Liver Microsomes of Mice, Rabbits, and Humans , 2004, Journal of Pharmacology and Experimental Therapeutics.
[22] G. Cavaletti,et al. Thalidomide sensory neurotoxicity , 2004, Neurology.
[23] M. Ermani,et al. Thalidomide neurotoxicity , 2004, Neurology.
[24] Y. Sugiyama,et al. Characterization of the Cellular Localization, Expression Level, and Function of SNP Variants of MRP2/ABCC2 , 2004, Pharmaceutical Research.
[25] S. Batalov,et al. A gene atlas of the mouse and human protein-encoding transcriptomes. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[26] A. Palumbo,et al. Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features , 2004, Acta neurologica Scandinavica.
[27] J. Marsden,et al. Thalidomide-induced neuropathy and genetic differences in drug metabolism , 1995, European Journal of Clinical Pharmacology.
[28] C. Hess,et al. Thalidomide-induced peripheral neuropathy , 1986, Journal of Neurology.
[29] Brad T. Sherman,et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.
[30] S. Rossi,et al. Thalidomide-induced neuropathy: A ganglionopathy? , 2003, Neurology.
[31] D. Cornblath,et al. Thalidomide-induced neuropathy , 2002, Neurology.
[32] J. Bouchard,et al. Erratum: The K-Cl cotransporter KCC3 is mutant in a severe peripheral neuropathy associated with agenesis of the corpus callosum (Nature Genetics (2002) 32(384-392)) , 2002 .
[33] Y. Ando,et al. Pharmacogenetic Associations of CYP2C19 Genotype with In Vivo Metabolisms and Pharmacological Effects of Thalidomide , 2002, Cancer biology & therapy.
[34] J. Bouchard,et al. The K–Cl cotransporter KCC3 is mutant in a severe peripheral neuropathy associated with agenesis of the corpus callosum , 2002, Nature Genetics.
[35] W. Figg,et al. Thalidomide metabolism by the CYP2C subfamily. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.
[36] Y. Sugiyama,et al. Polymorphisms in the ABCC2 (cMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5'-untranslated region and exon 28. , 2002, Drug metabolism and disposition: the biological fate of chemicals.
[37] J. Hirschhorn,et al. A comprehensive review of genetic association studies , 2002, Genetics in Medicine.
[38] S. Strittmatter,et al. Small Proline-Rich Repeat Protein 1A Is Expressed by Axotomized Neurons and Promotes Axonal Outgrowth , 2002, The Journal of Neuroscience.
[39] D. Ganesh Rao,et al. Thalidomide neuropathy: Role of F‐wave monitoring , 2000, Muscle & nerve.
[40] M. Dimopoulos,et al. Successful treatment of multiple myeloma relapsing after high-dose therapy and autologous transplantation with thalidomide as a single agent , 2000, Bone Marrow Transplantation.
[41] J. Shupack,et al. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. , 1996, Journal of the American Academy of Dermatology.